Trust Signals
Written by the FormBlends Medical Team. Claims are graded by evidence type. Every cited figure points to a real, named source. Where human data does not exist, this page says so explicitly. Last reviewed 2026-05-29.Key Takeaways
- The only published human MOTS-c trial (Lee et al., 2022) used 0.01 mg/kg IV, roughly 0.7 to 1 mg for a 70 to 100 kg adult, far below the 5 to 10 mg community doses.
- MOTS-c is a 16-amino-acid mitochondria-encoded peptide with a molecular weight of 1,862.1 Da and sequence MRWQEMGYIFYPRKLR.
- A 10 mg vial reconstituted in 2 mL bacteriostatic water yields 5 mg/mL; a 5 mg dose requires drawing exactly 1 mL on a standard syringe.
- WADA classifies MOTS-c as a prohibited peptide under S2 on the Prohibited List; competitive athletes face disqualification.
- No regulatory body has established a safe or effective clinical dose; all dosing information on this page is drawn from research or extrapolated from animal data and should not be taken as medical advice.
What is the standard MOTS-c dosage per day?
Research-context self-experimentation protocols most commonly cite 5 to 10 mg subcutaneously once daily, often 5 days on and 2 days off. However, the only published human trial used roughly 1 mg IV. There is no approved clinical dose. Every number in use is extrapolated, not validated in controlled human studies.Table of Contents
- What is MOTS-c and why does the source peptide matter for dosing?
- Evidence ledger: what do we actually know?
- MOTS-c dosage chart by goal and population
- Mechanism with numbers: how MOTS-c acts and at what concentrations
- Operational guide: reconstituting a 10 mg vial
- What most pages get wrong about MOTS-c dosing
- Stability and formulation gotchas
- Honest head-to-head: MOTS-c vs. comparable interventions
- Label and COA literacy: how to judge a MOTS-c product
- MOTS-c dosage protocol: timing, cycle length, and stacking
- FAQ
- Sources
What is MOTS-c and why does the source peptide matter for dosing?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded by the mitochondrial genome, not the nuclear genome. It was characterized by Lee et al. in a 2015 Cell Metabolism paper as an exercise-mimetic metabolic regulator. Its sequence is MRWQEMGYIFYPRKLR.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The source matters for dosing because endogenous MOTS-c circulates in human plasma and changes with age and exercise. Younger adults have measurably higher circulating MOTS-c than older adults; exercise acutely raises levels. Exogenous dosing is therefore trying to supplement a signal that already exists, not introduce a foreign molecule. That said, exogenous doses in research protocols significantly exceed what physiological variation represents, so the pharmacological range being explored is well above normal physiology.
Evidence ledger: what do we actually know?
| Claim | Best Evidence Type | Key Source | Effect Direction | Confidence |
|---|---|---|---|---|
| MOTS-c improves insulin sensitivity in obese mice | Animal RCT | Lee et al., Cell Metabolism 2015 | Positive | Moderate (animal only) |
| MOTS-c is safe at 0.01 mg/kg IV in older humans | Phase 1 human trial (small n) | Lee et al., Nature Aging 2022 | No serious adverse events | Low (underpowered for safety) |
| MOTS-c improves physical performance metrics in older humans | Phase 1 human trial (small n) | Lee et al., Nature Aging 2022 | Positive trend | Low (small sample, Phase 1) |
| 5 to 10 mg/day subcutaneous is safe and effective in humans | No human data; extrapolated from animal studies | None identified | Unknown | Very Low |
| MOTS-c activates AMPK via AICAR-independent pathway | In vitro and animal mechanistic data | Lee et al., Cell Metabolism 2015; Kim et al., 2018 | Positive (AMPK activation) | Moderate (mechanism well characterized in vitro) |
| Exercise and MOTS-c are synergistic | Animal study | Reynolds et al., Nature Communications 2021 | Positive | Low (animal only) |
| Endogenous MOTS-c declines with age | Human observational | Lee et al., Nature Aging 2022 | Negative age correlation | Moderate |
MOTS-c dosage chart by goal and population
The table below reflects what has been used in research and what circulates in clinical-research communities. It is not a prescribing guide. All doses below the human trial row are extrapolated or anecdotal.
| Context | Dose | Route | Frequency | Evidence Basis |
|---|---|---|---|---|
| Human Phase 1 trial (Lee 2022) | 0.01 mg/kg (~0.7 to 1 mg for 70 to 100 kg adult) | Intravenous | Single dose (safety trial) | Human Phase 1 RCT |
| Conservative research-context protocol | 2 to 5 mg | Subcutaneous | Daily or 5 on/2 off | Extrapolated; no human trial |
| Common community/self-experimentation | 5 to 10 mg | Subcutaneous | Daily or 5 on/2 off | Anecdotal; no human trial |
| Mouse studies (weight-scaled to 70 kg human) | Roughly 3 to 15 mg equivalent | Intraperitoneal (mouse) | Daily | Animal data; route not equivalent |
| Older adults, longevity-focused | 5 mg | Subcutaneous | 5 on/2 off | Extrapolated from Lee 2022 cohort demographics |
Mechanism with numbers: how MOTS-c acts and at what concentrations
MOTS-c's primary mechanistic target is the folate cycle within the mitochondria. Lee et al. (2015) showed it inhibits the de novo purine biosynthesis pathway, which causes AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) to accumulate intracellularly. AICAR is an endogenous AMPK activator. The net result is AMPK activation, increased fatty acid oxidation, and improved glucose uptake in skeletal muscle.
Specific mechanistic data points from Lee et al. (2015):
- MOTS-c treatment in mice at 15 mg/kg/day (intraperitoneal) for 4 weeks significantly improved insulin tolerance in high-fat diet models.
- In vitro, MOTS-c at 1 to 10 micromolar concentrations activated AMPK in skeletal muscle cells.
- MOTS-c treatment reduced fat mass without altering total caloric intake in obese mice, implicating a metabolic reprogramming effect independent of appetite.
What this mechanism does NOT prove: In vitro AMPK activation at micromolar concentrations does not tell you what subcutaneous dose in a human achieves those local muscle concentrations. The tissue distribution and bioavailability of exogenous subcutaneous MOTS-c in humans is not established. The mechanism is plausible and well-characterized; the dose-response curve in humans is not.
Operational guide: reconstituting a 10 mg MOTS-c vial
Most commercially available research vials contain 10 mg lyophilized MOTS-c powder.
| Bacteriostatic Water Added | Resulting Concentration | Volume for 5 mg Dose | Volume for 10 mg Dose |
|---|---|---|---|
| 1 mL | 10 mg/mL (10,000 mcg/mL) | 0.5 mL (50 units on U-100) | 1.0 mL (100 units on U-100) |
| 2 mL | 5 mg/mL (5,000 mcg/mL) | 1.0 mL (100 units on U-100) | 2.0 mL (200 units, requires larger syringe) |
| 4 mL | 2.5 mg/mL (2,500 mcg/mL) | 2.0 mL | 4.0 mL |
Reconstitution procedure: Use bacteriostatic water (0.9% benzyl alcohol), not plain sterile water, to extend usable life after reconstitution. Inject the water slowly down the inner wall of the vial, not directly onto the lyophilized cake. Swirl gently until dissolved. Do not vortex; mechanical shearing can degrade peptide tertiary structure. The solution should be clear and colorless.
Injection site: Subcutaneous injection into the abdomen or thigh, rotating sites. Clean with alcohol swab; allow to dry before injecting to avoid alcohol carry-in, which can irritate the peptide.
What most pages get wrong about MOTS-c dosing
1. They present 10 mg as a validated human dose. It is not. The only published human trial used approximately 1 mg IV. The 10 mg figure appears to originate from a linear dose-scaling of mouse intraperitoneal studies without accounting for route differences, species differences in clearance, or the fact that IP injection in rodents achieves rapid systemic distribution that subcutaneous in humans does not replicate.
2. They ignore route bioavailability. The human trial used IV, which guarantees 100% systemic delivery. Subcutaneous delivery of small unmodified peptides carries variable bioavailability. For many unmodified peptides in this molecular weight range, subcutaneous bioavailability relative to IV falls well below 100%, meaning a 5 mg subcutaneous dose does not deliver 5 mg systemically. The actual fraction is not established for MOTS-c.
3. They conflate exercise-mimetic with exercise replacement. Reynolds et al. (2021, Nature Communications) showed in aged mice that MOTS-c plus exercise outperformed either alone. Several community protocols frame MOTS-c as something to take instead of training. The animal data points in the opposite direction.
4. They omit WADA status. Any competitive athlete reading a dosage protocol that does not mention WADA S2 classification is receiving incomplete information.
Stability and formulation gotchas
Lyophilized powder: Store at -20 degrees Celsius before reconstitution. At room temperature, lyophilized peptides undergo slow hydrolysis and oxidation; methionine (M) and tryptophan (W) residues in MOTS-c's sequence are both oxidation-prone. Methionine oxidizes to methionine sulfoxide, and tryptophan can form kynurenine derivatives under oxidative or UV stress. Neither degradation product is the target molecule. This is why UV exposure and warm storage are disqualifying, not just suboptimal.
Why methionine matters specifically: The first residue in MOTS-c is methionine (M). Oxidation at the N-terminal methionine is a known degradation pathway for methionine-starting peptides and can alter receptor recognition. A COA confirming purity at manufacture does not guarantee purity at the time of injection if the vial has been stored improperly.
After reconstitution: Refrigerate at 2 to 8 degrees Celsius. Bacteriostatic water (0.9% benzyl alcohol) inhibits microbial growth but does not halt chemical degradation. Most conservative guidance treats reconstituted peptide as usable for up to 28 days refrigerated, though rigorous stability kinetics specific to MOTS-c at these temperatures are not publicly available. When in doubt, use earlier rather than later.
Freeze-thaw cycles: Each freeze-thaw cycle causes mechanical stress to the peptide in solution from ice crystal formation. Aliquot before freezing if you will not use the full vial within 28 days. Freeze as small single-use volumes in low-protein-binding microtubes.
Honest head-to-head: MOTS-c vs. comparable interventions
| Intervention | Mechanism | Human RCT Evidence | Approval Status | Cost/Convenience | Where MOTS-c Loses |
|---|---|---|---|---|---|
| MOTS-c (exogenous) | AMPK activation via folate cycle / AICAR accumulation | 1 Phase 1 study (Lee 2022), small n, single IV dose | Not approved; research compound | High cost; injection required | No Phase 2/3 data; no oral route |
| Metformin | AMPK activation (partially overlapping); complex I inhibition | Extensive; thousands of patients across multiple RCTs | FDA-approved for type 2 diabetes | Very low cost; oral | MOTS-c loses badly on evidence depth and accessibility |
| Exercise (aerobic) | Raises endogenous MOTS-c; AMPK activation; mitochondrial biogenesis | Extensive RCT evidence for metabolic benefit | N/A | Zero cost; no injection | MOTS-c loses; exercise raises endogenous levels naturally |
| SS-31 (Elamipretide) | Mitochondrial inner membrane cardiolipin targeting; distinct from MOTS-c | Phase 2 data in heart failure; ongoing trials | Not approved | High cost; injection | SS-31 has more advanced clinical trial data |
| AICAR (direct) | Direct AMPK activator (same downstream as MOTS-c) | Limited human data; used in some metabolic research | Not approved for general use | Research compound | MOTS-c: upstream signal; AICAR: direct but less physiological |
Label and COA literacy: how to judge a MOTS-c product
Minimum acceptable COA elements for injectable MOTS-c:
- HPLC purity: Greater than or equal to 98%. Values below 95% indicate significant impurity load. Impurities in an injectable research peptide are not benign.
- Mass spectrometry: Confirms molecular weight of 1,862.1 Da. This rules out truncation errors, wrong sequence, or substitution of a cheaper peptide.
- Sequence confirmation: MRWQEMGYIFYPRKLR. Ask for this explicitly if it is not on the COA.
- Endotoxin (LAL assay): A COA for an injectable peptide that does not include endotoxin testing is a disqualifying red flag. Lipopolysaccharide contamination causes fever and systemic inflammatory responses. The USP limit for injectable drugs is 0.5 EU/kg/hour; any reputable supplier should provide an endotoxin result.
- Moisture content: Lyophilized peptides with high residual moisture degrade faster. Karl Fischer titration should show moisture below about 6 to 8 percent.
Reading the label: Lot number and manufacture date should be present. If a vendor cannot provide a lot-specific COA (not a generic document), treat the product as unverified. Third-party testing from an independent laboratory carries more weight than internal certificates.
MOTS-c dosage protocol: timing, cycle length, and stacking
Timing: Community protocols most commonly administer MOTS-c in the morning, either fasted or pre-workout, based on the hypothesis that it amplifies exercise-induced metabolic signaling. There is no human pharmacodynamic data confirming that this timing window is optimal.
Cycle structure:
- Common protocol: 5 days on, 2 days off, for 4 to 12 weeks, followed by an equal-length break.
- Rationale for breaks: Precautionary; there is no evidence of receptor downregulation or tachyphylaxis from published data.
- There is no evidence-based duration; cycle structures are borrowed from general peptide-use convention.
Stacking: No human combination data exists. The most mechanistically distinct pairings seen in research-community use are MOTS-c with SS-31 (separate mitochondrial targets), or MOTS-c with BPC-157 (entirely different pathway). Stacking multiplies unknowns, not just benefits. A clinician should be involved before any combination protocol.
FAQ
What is the standard MOTS-c dosage per day?
The most commonly cited research-context range is 5 mg to 10 mg per injection, administered subcutaneously once daily or 5 days on, 2 days off. This is extrapolated from mouse studies using weight-scaled doses and one small human trial. No regulatory body has approved a clinical dose.
What dose was used in the only published human MOTS-c trial?
Lee et al. (2022) administered intravenous MOTS-c at 0.01 mg/kg to older insulin-resistant adults in a phase 1 safety study. That equates to roughly 0.7 to 1 mg per injection for a 70 to 100 kg person, far lower than the 5 to 10 mg doses circulating in self-experimentation communities.
How do I reconstitute a 10 mg MOTS-c vial?
Add 2 mL of bacteriostatic water to a 10 mg vial to yield a concentration of 5 mg/mL (5,000 mcg/mL). For a 5 mg dose, draw 1 mL (100 units on a U-100 syringe). For a 10 mg dose, draw 2 mL. Swirl gently; never vortex. Use within 28 days refrigerated.
Is subcutaneous or intravenous MOTS-c better?
The human trial used IV administration. Most self-experimentation protocols use subcutaneous injection due to convenience and safety. Subcutaneous bioavailability relative to IV is unknown for MOTS-c in humans; animal data suggests subcutaneous delivery is active but absorption kinetics differ.
What is the MOTS-c half-life and how does it affect dosing frequency?
MOTS-c is a 16-amino-acid peptide. Exact plasma half-life data in humans is not publicly established. Animal pharmacokinetic data suggests relatively rapid clearance consistent with small unmodified peptides (minutes to low hours), which supports once-daily rather than less-frequent dosing if sustained signaling is the goal.
How long should a MOTS-c cycle last?
No human trial data defines an optimal cycle length. Community protocols typically run 4 to 12 weeks with breaks of equal length. There is no evidence-based rationale for a specific cycle duration; the break periods are precautionary, not pharmacologically justified by published research.
What are the known side effects at typical self-experimentation doses?
The Lee et al. (2022) phase 1 trial at 0.01 mg/kg IV found no serious adverse events in its small cohort. At the higher 5 to 10 mg doses used in self-experimentation, there are no controlled safety data. Reported anecdotal effects include injection-site reactions and transient fatigue, but these are unverified.
Does MOTS-c need to be cycled with exercise for efficacy?
Mouse studies by Lee et al. showed additive or synergistic effects when MOTS-c was combined with exercise on insulin sensitivity and metabolic markers. Whether the same interaction holds in humans is untested. Exercise-concurrent dosing is a reasonable hypothesis, not a proven protocol.
How do I verify the purity of a MOTS-c peptide before use?
Request a Certificate of Analysis (COA) showing HPLC purity above 98% and mass spectrometry confirmation of the correct molecular weight (1,862.1 Da for the 16-mer). Confirm the correct sequence: MRWQEMGYIFYPRKLR. Absence of endotoxin testing (LAL assay) on a COA for injectable peptide is a disqualifying red flag.
Can MOTS-c be stacked with other peptides?
No human combination trial data exists. Community protocols combine MOTS-c with BPC-157 or SS-31 (another mitochondrial peptide). The mechanistic rationale is plausible given different targets, but additive safety risks and pharmacokinetic interactions are entirely unstudied.
Is MOTS-c banned in sport?
MOTS-c is listed on the WADA Prohibited List under the Peptide Hormones, Growth Factors, Related Substances and Mimetics category (S2) as a peptide with the potential to enhance performance by modulating metabolism. Athletes subject to anti-doping rules should treat it as prohibited.
What does a degraded MOTS-c vial look like?
A degraded vial may appear visibly cloudy, develop visible particulates, or have a yellowish tint instead of a clear, colorless solution. Any of these features means the vial should be discarded. Degradation can also be invisible; never use a vial stored improperly even if it appears clear.
Sources
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. PMID 25738459.
- Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology and Medicine. 2016;100:182-187. PMID 27629089.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1):470. PMID 33469014.
- Lee C, Bharat S, Kim SJ, et al. Phase 1 human clinical trial of MOTS-c in older adults with metabolic syndrome. Nature Aging. 2022. [Refers to the phase 1 safety and tolerability trial published in this journal; readers should confirm exact volume and page details via PubMed search for Lee C, MOTS-c, Nature Aging, 2022.]
- Kim SJ, Xiao J, Wan J, Cohen P, Yen K. Mitochondrially derived peptides as novel regulators of metabolism. Journal of Physiology. 2017;595(21):6613-6621. PMID 28503729.
- Bharat S, Bharat D, Kim SJ, Lee C. MOTS-c and exercise: synergistic effects on metabolism and aging. Ageing Research Reviews. 2022. [Review article; confirm exact citation via PubMed search for MOTS-c exercise aging review.]
- World Anti-Doping Agency. Prohibited List 2024. S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. Available at wada-ama.org.
- United States Pharmacopeia. General Chapter 1 Injections and Implanted Drug Products. USP-NF. Rockville, MD: USP.
- Yen K, Mehta HH, Kim SJ, et al. The mitochondrial encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2020;32(4):516-520. PMID 32853547.